Core Insights - Kodiak Sciences Inc. is focused on developing transformative therapeutics for retinal diseases, particularly glaucoma, and will present its pipeline programs at the ACS Fall 2025 Meeting [1][4] - Glaucoma affects approximately 76 million people globally and is the leading cause of irreversible blindness, with current treatments only addressing intraocular pressure [2] Company Overview - Kodiak Sciences is a precommercial biotechnology company dedicated to researching and commercializing innovative retinal therapeutics [6] - The company utilizes its Antibody Biopolymer Conjugate Drug (ABCD) platform to create dual-mechanism therapies targeting both neuroinflammation and intraocular pressure [3][8] Pipeline and Innovations - The company is advancing a dual-acting therapy that combines a small-molecule NLRP3 inhibitor with an IOP-lowering agent, delivered via a single intravitreal injection for quarterly dosing [3] - Kodiak is also innovating in clinical trial design through its VETi program, which employs AI and machine learning to enhance testing frequency and accuracy [3] Presentation Details - The presentation titled "Unmet clinical endpoints and therapeutics for retinal diseases: Challenges and innovations" will be delivered by Chief Scientific Officer Dolly S. Chang on August 19, 2025 [4]

Key Takeaways Kodiak posted a Q2 loss of $1.03 per share, missing estimates and widening from last year.Higher R&D costs reflect increased clinical activity across Kodiak's late-stage pipeline.Key tarcocimab and KSI-501 study results are due in 2026, with KSI-101 data expected by early 2027.Kodiak Sciences (KOD) incurred a loss of $1.03 per share in the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.01. The company had incurred a loss of 86 cents per share in the year-ago qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Exhibit 99.1 • Tarcocimab – Phase 3 topline data expected in 1Q 2026 (6 months) and 3Q 2026 (12 months) o Phase 3 GLOW2 diabetic retinopathy study – topline data on track for 1Q 2026 o Phase 3 DAYBREAK wet AMD study – topline data expected 3Q 2026 o Completed the manufacturing and release of BLA-facing commercial-scale batches in Kodiak's URSUS facility • KSI-501 – Phase 3 topline data expected in 3Q 2026 (12 months) o Phase 3 DAYBREAK wet AMD study – topline data expected 3Q 2026 o Planning for second Phas ...

PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025."Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets –tarcocimab, KSI-501 and KSI-101– underscoring their transformative potential in retinal disease treatment," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Scien ...

Summary of Kodiak Sciences (KOD) Investor R&D Day - July 16, 2025 Company Overview - **Company**: Kodiak Sciences (KOD) - **Event**: Investor R&D Day - **Date**: July 16, 2025 - **Market Cap**: $250 million [10] Key Clinical Assets - **Late Stage Clinical Assets**: - **Tarcosumab** - **KSI-501** - **KSI-101** [2][5] Core Points and Arguments 1. **KSI-101 Performance**: - KSI-101 is showing strong Phase Ib data, outperforming expectations with over 10 letters mean gain in visual acuity, compared to the expected 7-8 letters [11] - Nearly all patients are dry on intraretinal fluid and subretinal fluid by week 12, indicating high efficacy [11] 2. **Unmet Need in Macular Edema**: - KSI-101 addresses macular edema secondary to inflammation, a leading cause of blindness in working-age populations [10][12] - The potential for KSI-101 to unify treatment across diverse patient types is emphasized, akin to the early anti-VEGF treatments [12][13] 3. **Commercial Opportunity**: - Estimated prevalence of over 450,000 patients with macular edema in the U.S., with 300,000 trial-eligible for KSI-101 [17] - KSI-101 is positioned as a first-line treatment for severe cases and may be first choice for intraocular injection [17] 4. **Clinical Trial Design**: - PEEK and PINNACLE studies for KSI-101 are live and screening patients, showcasing efficient operationalization [18] - The DAYBREAK study will compare Tarcosumab and KSI-501 against EYLEA, focusing on both immediacy and durability [20][21] 5. **Durability and Efficacy**: - Kodiak's ABC platform science aims to provide both strong immediacy and durability in treatment, with a mean ocular half-life of 20 days for their conjugates [22][59] - The need for a biologic that combines rapid drying capacity with increased durability is highlighted as a significant unmet need in the market [24][83] 6. **Market Landscape**: - The retinal vascular diseases market is described as commercially attractive, with a global market exceeding $20 billion [31] - Kodiak's focus on retina is contrasted with the complexities and costs associated with oncology and obesity markets [31][32] Additional Important Insights - **Technological Leadership**: - Kodiak operates its own in-house CRO, enhancing efficiency and connection to the physician community [19] - The company is also developing AI technology (Vedi program) aimed at improving treatment outcomes [29] - **Patient-Centric Approach**: - Emphasis on patient-centric trial designs, allowing for flexible dosing based on individual patient needs [72][73] - The importance of addressing the heterogeneity of patient responses to treatments is acknowledged [58] - **Future Outlook**: - Anticipated BLA filings for Tarcosumab and KSI-101 in 2027, with multiple registrational studies reading out in the next 6 to 18 months [26][34] - Kodiak's proprietary science and manufacturing capabilities position it well for future growth in the retinal disease market [27][28] This summary encapsulates the key points discussed during the Kodiak Sciences Investor R&D Day, focusing on the company's clinical assets, market opportunities, and strategic direction in the retinal disease sector.

Core Insights - Kodiak Sciences Inc. is hosting an investor R&D Day webcast on July 16, 2025, from 4:00 pm ET to 5:30 pm ET, focusing on its late-phase clinical assets [1][2]. Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on retinal diseases, aiming to develop transformative therapeutics to prevent and treat blindness globally [4]. - The company utilizes its ABC Platform®, which integrates protein-based and chemistry-based therapies, as the foundation of its discovery engine [4]. - Kodiak's pipeline includes three late-phase clinical assets, all targeting Phase 3 topline data expected in 2026 [4]. Event Details - The webcast will feature presentations from Kodiak's senior leadership and industry experts, providing a comprehensive overview of its three late-phase clinical assets: tarcocimab, KSI-501, and KSI-101 [2]. - Registration for the event is available online, and a recording will be accessible 24 hours post-event [3].

Core Insights - Kodiak Sciences Inc. is presenting KSI-101, a bispecific investigational biologic targeting macular edema secondary to inflammation, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro [1][6] - The company aims to address the significant unmet need in treating macular edema caused by inflammation, which can lead to vision loss [3][4] Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on developing therapeutics for retinal diseases, utilizing its ABC Platform for innovative drug design [8][9] - The company is advancing its pipeline, which includes three late-phase clinical assets expected to deliver Phase 3 topline data in 2026 [9] Product Details - KSI-101 is a high-strength (100 mg/mL) bispecific protein designed to target both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF), addressing the dual mechanisms of macular edema [6][5] - The ongoing Phase 1b study, APEX, is evaluating the safety and tolerability of KSI-101, with plans to progress into dual Phase 2b/3 studies [7]

Core Viewpoint - Kodiak Sciences Inc. has seen a 10.5% increase in share price over the past month, outperforming the S&P 500, but estimates have trended downward, indicating potential challenges ahead [1][2]. Group 1: Earnings and Estimates - The consensus estimate for Kodiak Sciences has shifted downward by 10.35% over the past month [2]. - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4]. Group 2: VGM Scores - Kodiak Sciences has a subpar Growth Score of D and a Momentum Score of F, with an overall aggregate VGM Score of F, placing it in the lowest quintile for investment strategies [3]. Group 3: Industry Performance - Kodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry, where Apellis Pharmaceuticals has gained 17.7% over the past month [5]. - Apellis Pharmaceuticals reported revenues of $166.8 million, reflecting a year-over-year decline of 3.2%, and is expected to post a loss of $0.44 per share for the current quarter, indicating a 57.1% change from the previous year [6].

Summary of Kodiak Sciences (KOD) 2025 Conference Call Company Overview - **Company**: Kodiak Sciences - **Date**: June 05, 2025 - **Focus**: Development of biologic therapies for retinal diseases, particularly wet AMD, diabetic retinopathy, and retinal vein occlusion Key Points Industry and Product Pipeline - Kodiak is actively engaged in multiple clinical studies, with a focus on its lead product, **tarcosumab**, an antibody conjugate targeting retinal diseases [2][4] - The **GLOW 2 study** for tarcosumab has been fully enrolled, with top-line data expected in February 2026 [4][5] - The **DAYBREAK study** is also underway, combining tarcosumab with KSI 501, a bispecific conjugate, targeting wet AMD [4][11] Clinical Trial Insights - Tarcosumab has shown the **world's best durability** as a biologic in retinal treatments, with a mean half-life of **20 days** compared to other biologics that average **6-8 days** [8][10] - The new formulations aim to improve both **efficacy** and **immediacy** of action, addressing previous concerns about the size of the conjugates affecting performance [7][8] - The **Doctor study** is anticipated to have a high probability of success, with results expected in Q1 2026 [14][15] Safety and Efficacy - Concerns regarding intraocular inflammation (IOI) have been addressed, with Kodiak reporting that their rates of inflammation are comparable or better than competitors [30][31] - The new formulation of tarcosumab has shown **fewer cataract adverse events** compared to Eylea, which is significant for patient safety [33][34] Market Position and Competitive Landscape - Kodiak aims to differentiate its products from existing treatments like **Eylea** and **Vobizmo** by offering superior durability, efficacy, and safety [20][21] - The company is preparing to file for FDA approval for multiple indications, including AMD, diabetic retinopathy, and retinal vein occlusion [19][20] Financial Position - Kodiak has over **$100 million** in cash, with a quarterly burn rate of approximately **$30 million** [87][88] - The company is exploring various financing options to support its ongoing clinical programs and operational needs [88] Future Outlook - Kodiak is optimistic about the upcoming data readouts from its phase three studies, which are expected to provide critical insights into the efficacy and safety of its therapies [76][78] - The company is also preparing to present more data on its **KSI 501 program** at the upcoming analyst day, highlighting its potential in treating macular edema secondary to inflammation [71][72] Additional Insights - The discussion highlighted the potential for **macular edema secondary to inflammation (MESI)** as a significant market opportunity, with Kodiak's bispecific approach expected to outperform competitors [53][68] - The company is committed to leveraging insights from ongoing studies to refine its approach and enhance the likelihood of successful outcomes in its clinical trials [85][86]